This title appears in the Scientific Report :
2023
Please use the identifier:
http://dx.doi.org/10.1055/a-2183-8269 in citations.
Pharmakokinetik: Vilobelimab hemmt C5a bei Intensivpatient*innen mit COVID-19
Pharmakokinetik: Vilobelimab hemmt C5a bei Intensivpatient*innen mit COVID-19
Saved in:
Personal Name(s): | Simon, Annika |
---|---|
Fritsch, Sebastian | |
Contributing Institute: |
Center for Advanced Simulation and Analytics; CASA Jülich Supercomputing Center; JSC |
Published in: | Journal Club AINS, 12 (2023) 04, S. 189 - 191 |
Published in: |
Lim EHT et al. Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients. Intensive Care Med Exp 2023; 11: DOI: 10.1186/s40635-023-00520-8 |
Imprint: |
Stuttgart
Thieme
2023
|
DOI: |
10.1055/a-2183-8269 |
Document Type: |
Book Review Journal Article |
Research Program: |
SDI-S: Smart Data Innovation Services - Experimentelle Erprobung und Entwicklung von KI-Dienstverbünden für Innovationen auf industriellen Daten Cross-Domain Algorithms, Tools, Methods Labs (ATMLs) and Research Groups |
Publikationsportal JuSER |
Description not available. |